Great Lakes Advisors LLC Decreases Holdings in Prestige Consumer Healthcare Inc. $PBH

Great Lakes Advisors LLC trimmed its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 33.9% during the third quarter, Holdings Channel reports. The fund owned 79,435 shares of the company’s stock after selling 40,731 shares during the period. Great Lakes Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $4,957,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Assenagon Asset Management S.A. purchased a new position in Prestige Consumer Healthcare in the 3rd quarter valued at approximately $1,890,000. Allspring Global Investments Holdings LLC grew its position in shares of Prestige Consumer Healthcare by 4.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after purchasing an additional 70,376 shares in the last quarter. AXQ Capital LP bought a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at $694,000. Tributary Capital Management LLC lifted its holdings in Prestige Consumer Healthcare by 157.3% during the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock worth $23,675,000 after purchasing an additional 231,969 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Prestige Consumer Healthcare by 13.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,571 shares of the company’s stock worth $765,000 after purchasing an additional 1,134 shares during the period. 99.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Jefferies Financial Group reaffirmed a “hold” rating and set a $66.00 price objective on shares of Prestige Consumer Healthcare in a research note on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Oppenheimer reduced their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Finally, Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and an average price target of $84.50.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the sale, the vice president owned 42,329 shares of the company’s stock, valued at $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.40% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $64.54 on Friday. The firm has a 50 day simple moving average of $62.52 and a two-hundred day simple moving average of $64.39. The stock has a market cap of $3.10 billion, a PE ratio of 16.01, a P/E/G ratio of 2.01 and a beta of 0.40. Prestige Consumer Healthcare Inc. has a one year low of $57.25 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The company had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. During the same period in the previous year, the firm posted $1.09 EPS. The firm’s revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).